Keros Therapeutics (NASDAQ:KROS) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings data on Wednesday. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13), Briefing.com reports. The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter last year, the company earned ($1.33) earnings per share.

Keros Therapeutics Stock Up 1.2 %

Keros Therapeutics stock traded up $0.83 during midday trading on Thursday, reaching $67.28. The stock had a trading volume of 259,878 shares, compared to its average volume of 368,802. Keros Therapeutics has a 52-week low of $27.31 and a 52-week high of $73.00. The company has a fifty day moving average of $56.87 and a 200 day moving average of $51.89. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -13.14 and a beta of 1.23.

Insider Activity

In related news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 22.90% of the company’s stock.

Analysts Set New Price Targets

KROS has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday. Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Scotiabank initiated coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Guggenheim initiated coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Finally, Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research report on Tuesday. They set a “buy” rating for the company. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.